|
rs6939340
|
CASC15;NBAT1
|
Neuroblastoma
|
|
0.840 |
GeneticVariation |
BEFREE |
We also confirmed that rs6939340 A>G (G versus A: OR=1.30, 95% CI=1.13-1.50) and rs110419 G>A (A versus G: OR=1.37, 95% CI=1.19-1.58) were associated with increased neur</span>oblastoma risk for all subjects.
|
29024823 |
2017 |
|
rs6939340
|
CASC15;NBAT1
|
Neuroblastoma
|
|
0.840 |
GeneticVariation |
BEFREE |
In the Henan population, only the rs6939340 G>A variant homozygote AA was associated with decreased neuroblastoma risk [AA vs. GG: adjusted odds ratio (OR) = 0.47, 95% confidence interval (CI) = 0.23-0.98; <i>P</i>=0.045].
|
29207648 |
2017 |
|
rs6939340
|
CASC15;NBAT1
|
Neuroblastoma
|
|
0.840 |
GeneticVariation |
BEFREE |
We found that the rs6939340 A allele carriers were associated with significantly decreased neuroblastoma susceptibility (AG vs. GG: adjusted OR = 0.54, 95 % CI = 0.38-0.77; AA vs. GG: adjusted OR = 0.49, 95 % CI = 0.25-0.93; and AA/AG vs. GG: adjusted OR = 0.53, 95 % CI = 0.38-0.74) after adjustment for age and gender.
|
26307394 |
2016 |
|
rs6939340
|
CASC15;NBAT1
|
Neuroblastoma
|
|
0.840 |
GeneticVariation |
BEFREE |
Homozygosity for the at-risk G allele of the most significantly associated SNP, rs6939340, resulted in an increased likelihood of the development of neuroblastoma (odds ratio, 1.97; 95% confidence interval, 1.58 to 2.45).
|
18463370 |
2008 |
|
rs6939340
|
CASC15;NBAT1
|
Neuroblastoma
|
G |
0.840 |
GeneticVariation |
GWASDB |
Homozygosity for the at-risk G allele of the most significantly associated SNP, rs6939340, resulted in an increased likelihood of the development of neuroblastoma (odds ratio, 1.97; 95% confidence interval, 1.58 to 2.45).
|
18463370 |
2008 |
|
rs6939340
|
CASC15;NBAT1
|
Neuroblastoma
|
G |
0.840 |
GeneticVariation |
GWASCAT |
Homozygosity for the at-risk G allele of the most significantly associated SNP, rs6939340, resulted in an increased likelihood of the development of neuroblastoma (odds ratio, 1.97; 95% confidence interval, 1.58 to 2.45).
|
18463370 |
2008 |
|
rs4712656
|
CASC15;NBAT1
|
Red Blood Cell Count measurement
|
|
0.700 |
GeneticVariation |
GWASCAT |
Leveraging Polygenic Functional Enrichment to Improve GWAS Power.
|
30595370 |
2019 |
|
rs4712656
|
CASC15;NBAT1
|
Diastolic blood pressure
|
G |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation.
|
27841878 |
2017 |
|
rs4712656
|
CASC15;NBAT1
|
Systolic Pressure
|
G |
0.700 |
GeneticVariation |
GWASCAT |
Genome-wide association analyses using electronic health records identify new loci influencing blood pressure variation.
|
27841878 |
2017 |
|
rs4712656
|
CASC15;NBAT1
|
Neuroblastoma
|
C |
0.700 |
GeneticVariation |
GWASCAT |
Common variants upstream of MLF1 at 3q25 and within CPZ at 4p16 associated with neuroblastoma.
|
28545128 |
2017 |
|
rs6939340
|
CASC15;NBAT1
|
Nasopharyngeal carcinoma
|
|
0.700 |
GeneticVariation |
GWASDB |
A genome-wide association study of nasopharyngeal carcinoma identifies three new susceptibility loci.
|
20512145 |
2010 |
|
rs6939340
|
CASC15;NBAT1
|
Childhood Neuroblastoma
|
|
0.040 |
GeneticVariation |
BEFREE |
In the Henan population, only the rs6939340 G>A variant homozygote AA was associated with decreased neuroblastoma risk [AA vs. GG: adjusted odds ratio (OR) = 0.47, 95% confidence interval (CI) = 0.23-0.98; <i>P</i>=0.045].
|
29207648 |
2017 |
|
rs6939340
|
CASC15;NBAT1
|
Central neuroblastoma
|
|
0.040 |
GeneticVariation |
BEFREE |
We also confirmed that rs6939340 A>G (G versus A: OR=1.30, 95% CI=1.13-1.50) and rs110419 G>A (A versus G: OR=1.37, 95% CI=1.19-1.58) were associated with increased neur</span>oblastoma risk for all subjects.
|
29024823 |
2017 |
|
rs6939340
|
CASC15;NBAT1
|
Central neuroblastoma
|
|
0.040 |
GeneticVariation |
BEFREE |
In the Henan population, only the rs6939340 G>A variant homozygote AA was associated with decreased neuroblastoma risk [AA vs. GG: adjusted odds ratio (OR) = 0.47, 95% confidence interval (CI) = 0.23-0.98; <i>P</i>=0.045].
|
29207648 |
2017 |
|
rs6939340
|
CASC15;NBAT1
|
Childhood Neuroblastoma
|
|
0.040 |
GeneticVariation |
BEFREE |
We also confirmed that rs6939340 A>G (G versus A: OR=1.30, 95% CI=1.13-1.50) and rs110419 G>A (A versus G: OR=1.37, 95% CI=1.19-1.58) were associated with increased neur</span>oblastoma risk for all subjects.
|
29024823 |
2017 |
|
rs6939340
|
CASC15;NBAT1
|
Central neuroblastoma
|
|
0.040 |
GeneticVariation |
BEFREE |
We found that the rs6939340 A allele carriers were associated with significantly decreased neuroblastoma susceptibility (AG vs. GG: adjusted OR = 0.54, 95 % CI = 0.38-0.77; AA vs. GG: adjusted OR = 0.49, 95 % CI = 0.25-0.93; and AA/AG vs. GG: adjusted OR = 0.53, 95 % CI = 0.38-0.74) after adjustment for age and gender.
|
26307394 |
2016 |
|
rs6939340
|
CASC15;NBAT1
|
Childhood Neuroblastoma
|
|
0.040 |
GeneticVariation |
BEFREE |
We found that the rs6939340 A allele carriers were associated with significantly decreased neuroblastoma susceptibility (AG vs. GG: adjusted OR = 0.54, 95 % CI = 0.38-0.77; AA vs. GG: adjusted OR = 0.49, 95 % CI = 0.25-0.93; and AA/AG vs. GG: adjusted OR = 0.53, 95 % CI = 0.38-0.74) after adjustment for age and gender.
|
26307394 |
2016 |
|
rs6939340
|
CASC15;NBAT1
|
Central neuroblastoma
|
|
0.040 |
GeneticVariation |
BEFREE |
Homozygosity for the at-risk G allele of the most significantly associated SNP, rs6939340, resulted in an increased likelihood of the development of neuroblastoma (odds ratio, 1.97; 95% confidence interval, 1.58 to 2.45).
|
18463370 |
2008 |
|
rs6939340
|
CASC15;NBAT1
|
Childhood Neuroblastoma
|
|
0.040 |
GeneticVariation |
BEFREE |
Homozygosity for the at-risk G allele of the most significantly associated SNP, rs6939340, resulted in an increased likelihood of the development of neuroblastoma (odds ratio, 1.97; 95% confidence interval, 1.58 to 2.45).
|
18463370 |
2008 |